Advertisement

Search Results

Advertisement



Your search for all items matches 19814 pages

Showing 1 - 50


hepatobiliary cancer

Role of IL-6/JAK1 Pathway in the Treatment of Hepatocellular Carcinoma

A recent study published by Chan et al in the Journal of Clinical Investigation found a cellular pathway associated with cancer may be beneficial in reducing side effects and extending duration of immunotherapy in some patients with hepatocellular carcinoma. IL-6/JAK1 Pathway Researchers...

issues in oncology

Fragility Analysis of Phase III Trials Supporting FDA Approval of Anticancer Drugs

In an analysis reported in The Lancet Oncology, Del Paggio and Tannock found that many phase III trials supporting U.S. Food and Drug Administration (FDA) approval of anticancer drugs have a low fragility index—a measure of how many people in a study would have had to have a different outcome ...

colorectal cancer
issues in oncology

Rise in Early-Onset Colorectal Cancer Not Fully Aligned With Screening Trends

A new study finds that trends in colonoscopy rates did not fully align with recent increases in colorectal cancer incidence in younger adults. The findings were published by Fedewa et al in the Journal of Medical Screening. Colorectal cancer incidence rates are declining in adults older than...

issues in oncology
immunotherapy

Incidence of Olaratumab Infusion-Related Reactions

In a study reported in the Journal of Oncology Practice, Van Tine et al found that infusion-related reactions occurred in 14.4% of patients receiving olaratumab in clinical trials, with grade ≥ 3 events occurring in 2.3%. (Olaratumab was withdrawn from the global market on April 25, 2019, based...

skin cancer

Does Size of Surgical Excision Margins for Thick Localized Cutaneous Melanoma Affect Survival Outcomes?

In a nearly 20-year follow-up of a Scandinavian trial reported in The Lancet, Utjés et al found no difference in survival outcomes with 2-cm vs 4-cm surgical excision margins for primary localized cutaneous melanoma with a thickness > 2 mm. The previous report from the trial showed no...

pancreatic cancer

Biliary Microbiome Altered in Patients Undergoing Surgery After Neoadjuvant Therapy for Pancreatic Cancer

The biliary microbiome was altered in patients who received neoadjuvant therapy prior to undergoing surgery for pancreatic cancer, according to a study published by Goel et al in HPB. Additionally, more bacteria in patients who underwent surgery after neoadjuvant therapy were resistant to...

breast cancer

Role of Regulatory T Cells in Predicting Breast Cancer Relapse

Blood and intratumoral regulatory T-cell activity may one day provide a method for predicting breast cancer relapse, according to findings published by Wang et al in Nature Immunology. “This is the first success linking a solid tumor with blood biomarkers—an indicator of whether a...

solid tumors
issues in oncology

Receipt of Radioactive Iodine Treatment for Differentiated Thyroid Cancer and Perception of Patient Choice

In a study reported in the Journal of Clinical Oncology, Wallner et al found that many patients with differentiated thyroid cancer reported feeling they had no choice in receipt of radioactive iodine treatment. As stated by the investigators, “For many patients with differentiated thyroid...

lymphoma
survivorship

Long-Term Health Outcomes After Lymphome Malin de Burkitt Chemotherapy for Pediatric Mature B-Cell Non-Hodgkin Lymphoma

In a study reported in the Journal of Clinical Oncology, Ehrhardt et al found that long-term health outcomes were comparable in patients receiving contemporary Lymphome Malin de Burkitt (LMB) vs non-LMB chemotherapy regimens for pediatric mature B-cell non-Hodgkin lymphoma, except for adverse...

hepatobiliary cancer

Neoadjuvant Radiotherapy vs Surgery Alone for Resectable Hepatocellular Carcinoma With Tumor Thrombus

In a Chinese study reported in the Journal of Clinical Oncology, Wei et al found that neoadjuvant three-dimensional conformal radiotherapy improved outcomes vs hepatectomy alone in patients with resectable hepatocellular carcinoma with portal vein tumor thrombus. Study Details In the multicenter...

Biden Cancer Initiative Suspends All Operations

Today, the Biden Cancer Initiative announced it would suspend all operations. The Initiative, which launched on June 26, 2017, is an independent nonprofit organization that was built on the goals of the White House Cancer Moonshot program created by President Barack Obama and led by Vice President ...

sarcoma

Addition of Preoperative NBTXR3 to Radiotherapy in Locally Advanced Soft-Tissue Sarcoma

In the phase II/III Act.In.Sarc trial reported in The Lancet Oncology, Bonvalot et al found that preoperative addition of the radioenhancer hafnium oxide nanoparticle NBTXR3 to radiotherapy may improve outcomes in patients with locally advanced soft-tissue sarcoma. The agent acts to increase...

hepatobiliary cancer

Ivosidenib for Advanced IDH1-Mutated Advanced Cholangiocarcinoma

Ivosidenib, a small-molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), is currently being studied in a phase I clinical trial assessing its efficacy in patients with IDH1-mutated solid tumors. In a report published by Lowery et al in The Lancet Gastroenterology & Hepatology, researchers...

issues in oncology

Economic Burden of Cancer in the United States in 2015

There were more than 8.7 million person-years of life lost and $94.4 billion in earnings lost due to cancer among people aged 16 to 84 in the United States in 2015. The calculation comes from a new report published by Islami et al in JAMA Oncology. Cancer is the second-leading cause of death...

solid tumors

Subtypes of Pancreatic Neuroendocrine Tumors and Effect on Disease Recurrence

Researchers have discovered two distinct subtypes of pancreatic neuroendocrine tumors (pNETs) associated with different risks of recurrence following surgical treatment. The finding could yield predictive tests while focusing vigilant follow-up monitoring on patients with pNETs that have a higher...

leukemia
survivorship

Anesthesia Exposure and Neurocognitive and Neuroimaging Outcomes in Long-Term Survivors of Childhood ALL

In a study reported in JAMA Oncology, Banerjee et al found that higher cumulative anesthesia exposure and duration of exposure during treatment of childhood acute lymphoblastic leukemia (ALL) may be associated with adverse neurocognitive and abnormal neuroimaging outcomes in long-term survivors....

gynecologic cancers

Is There an Increased Long-Term Risk for Ovarian Cancer After Assisted Reproductive Technology?

Fertility treatment is not associated with an increased long-term risk of ovarian cancer, according to the results of a large-scale multicenter study presented by Spaan et al at the 35th Annual Meeting of the European Society of Human Reproduction and Embryology (Abstract O-183). The findings,...

gynecologic cancers
lung cancer
lymphoma
skin cancer
multiple myeloma

FDA Pipeline: Designations and Applications Granted in Lymphoma, Small Cell Lung Cancer, Multiple Myeloma, and More

Recently, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to a phospholipid-drug conjugate in diffuse large B-cell lymphoma; granted Orphan Drug designation to an immunotherapy for small cell lung cancer (SCLC); accepted supplemental biologics license applications (sBLAs) ...

bladder cancer

Study Identifies Key Biologic Features of Upper Tract Urothelial Carcinoma

A new study published by Robinson et al in Nature Communications aimed to learn more about the biologic characteristics of upper tract urothelial carcinoma to help develop more targeted therapies. “We discovered the defining biologic characteristics of [upper tract urothelial tumors] that...

breast cancer
survivorship

Intervention to Promote Breast Cancer Surveillance in Childhood Cancer Survivors Who Received Chest Radiotherapy

In the EMPOWER trial, which took place within the larger Childhood Cancer Survivor Study (CCSS) and was reported in the Journal of Clinical Oncology, Oeffinger et al found that an intervention consisting of mailed educational materials followed by telephone-delivered counseling led to an increased...

leukemia

Substitution of Clofarabine for Anthracycline/Etoposide in Induction Therapy for Pediatric Acute Myeloid Leukemia

In the phase III AML08 trial reported in the Journal of Clinical Oncology, Rubnitz et al found that the use of clofarabine instead of an anthracycline and etoposide in the first course of induction therapy may be a feasible strategy in pediatric patients with acute myeloid leukemia. The trial,...

Friends of Cancer Research Launches Next Phase in Real-World Evidence Initiative

Friends of Cancer Research (Friends) is launching the next phase of its Real-World Evidence (RWE) pilot project after a broad stakeholder meeting in February 2019. At the meeting, the U.S. Food and Drug Administration (FDA) and various data partners expressed interest in...

lung cancer
cost of care

Cost-Effectiveness of Single-Marker Genetic Testing vs Multigene Panel Sequencing in Advanced NSCLC

The results of an economic modeling study to estimate the cost-effectiveness of multigene panel sequencing as compared to standard-of-care single-gene tests for patients with advanced non–small cell lung cancer (NSCLC) showed that multigene panel sequencing tests are moderately...

hepatobiliary cancer

KIR-HLA System Gene Loci Imbalance and Biliary Tract Cancer

Patients with biliary tract cancer have an altered genetic architecture in some immune system receptor systems, according to research published by Cornillet et al in Gastroenterology. Research Findings Researchers at Karolinska Institutet investigated the genetic architecture of two large genetic ...

issues in oncology
symptom management
immunotherapy

Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events

In a study reported in JAMA Oncology, Simonaggio et al found that rechallenge with an immune checkpoint inhibitor after occurrence of immune-related adverse events was associated with occurrence of an immune-related adverse event in approximately half of patients, with no increase in severity....

issues in oncology

Does Centralization of High-Risk Cancer Surgery in Hospital Systems Improve Outcomes?

In a study reported in the Journal of Clinical Oncology, Sheetz et al identified the degree of centralization of high-risk cancer surgeries within hospital systems and found improved short-term outcomes with increased centralization among Medicare patients. Study Details The study involved...

colorectal cancer

ReDOS: Regorafenib Dose-Escalation Strategy in Refractory Advanced Colorectal Cancer

In the phase II ReDOS trial reported in The Lancet Oncology, Bekaii-Saab et al found that a regorafenib dose-escalation strategy compared favorably with standard dosing in regard to toxicity profile and activity in patients with refractory advanced colorectal cancer.    Study...

immunotherapy
lymphoma

Combination Therapy With Immunochemotherapy and an Antibody-Drug Conjugate in DLBCL

As reported in The Lancet Oncology, Hervé Tilly, MD, and colleagues found that the combination of polatuzumab vedotin, an antibody-drug conjugate targeting the CD79b component of the B-cell receptor, with immunochemotherapy showed high response rates in the phase II portion of a phase I/II study in ...

multiple myeloma

Effect of Bortezomib/Dexamethasone Plus Pomalidomide on Progression-Free Survival in Multiple Myeloma Pretreated With Lenalidomide

In the phase III OPTIMISMM trial, reported by Paul G. Richardson, MD, and colleagues in The Lancet Oncology, researchers found that the addition of pomalidomide to bortezomib/dexamethasone improved progression-free survival in relapsed or refractory multiple myeloma previously treated with...

gynecologic cancers

Addition of Antiangiogenic Agent to First-Line Carboplatin/Paclitaxel in Ovarian Cancer

In a phase III trial (TRINOVA-3/ENGOT-ov2/GOG- 3001) reported in The Lancet Oncology, Ignace Vergote, PhD, and colleagues found that addition of the antiangiogenic agent trebananib to carboplatin/ paclitaxel did not improve progression-free survival in first-line treatment of advanced ovarian...

A Pioneering Surgeon Who Opened Doors for Others, LaSalle D. Leffall, Jr, MD, Dies at 89

Lifting himself from the barriers of the segregated South, LaSalle D. Leffall, Jr, MD, would become a nationally regarded oncologic surgeon who opened doors for other in the medical profession. His career was distinguished by “firsts,” such as the first African America President of both the...

colorectal cancer
genomics/genetics

Henry T. Lynch, MD, Trailblazer in Hereditary Cancers, Dies at 91

Henry T. Lynch, MD, widely known as “the father of cancer genetics,” had an early life that could have been lifted from the pages of a Louis L’Amour novel. He dropped out of high school and using a falsified birth certificate joined the U.S. Navy at 16 years old, serving as a gunner on a marine...

integrative oncology

Chaga Mushroom

The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, explore the current...

multiple myeloma
immunotherapy

How Immunologic Dysregulation in the Multiple Myeloma Microenvironment May Affect Response to CAR T-Cell Therapy

Despite an avalanche of novel therapies approved by the U.S. Food and Drug Administration (FDA) over the past decade in the treatment of multiple myeloma, including proteasome inhibitors and immunomodulatory drugs, this blood cancer remains largely incurable, and nearly 13,000 people are expected...

breast cancer
gastroesophageal cancer
gastrointestinal cancer

FDA Approves New Trastuzumab Biosimilar

On June 14, the U.S. Food and Drug Administration (FDA) approved trastuzumab-anns (Kanjinti) for all approved indications of the reference product trastuzumab (Herceptin): for the treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction...

The Bomb

I sit paralyzed at my desk. Everyone else has left the clinic. I can hear the sound of the broom in the hall as the after-hours cleaning begins. No phones ring, no patients hurry to appointments, no chatter lingers in the air. The silence is oppressive, the air is heavy, and the distance from my...

Growing Up in a Medical Family Planted the Seed for a Career in Oncology for Karen Gelmon, MD

Karen Gelmon, MD, was born and reared in Saskatoon, the largest city in the Canadian province of Saskatchewan. It is surrounded by vast prairie and situated along the Trans-Canada Yellowhead Highway and is home to the University of Saskatchewan. “We lived close to the University,” she shared. “My...

gastroesophageal cancer
gastrointestinal cancer

Trifluridine/Tipiracil in Recurrent, Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

In the Clinic provides overviews of novel hematology and oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On February 22, trifluridine/tipiracil...

Endowment Helps George Washington University Cancer Center to Create Position of Dr. Cyrus Katzen Family Director

The George Washington University (GW) Cancer Center has announced the establishment of the Dr. Cyrus Katzen Family Director of the GW Cancer Center, thanks to a gift from GW alumnus and former Board of Trustee member Jay Katzen, MD. The gift will support the ongoing growth and expansion of the GW ...

Queen Elizabeth II Bestows Honor on V. Craig Jordan, OBE, PhD, DSc, FMedSci

On June 7, 2019, Professor V. Craig Jordan, OBE, PhD, DSc, FMedSci, was appointed Companion of the Most Distinguished Order of St. Michael and St. George by Queen Elizabeth II on her 93rd birthday. Each year, the Queen recognizes the achievements of people from across the British Commonwealth. Dr. ...

Willie Underwood III, MD, MSc, MPH, Elected to AMA Board of Trustees

The American Medical Association (AMA) announced the election of Willie Underwood III, MD, MSc, MPH, a urologist based in Buffalo, New York, to its Board of Trustees. A board-certified urologic surgeon specializing in prostate cancer, Dr. Underwood has been an active leader in organized medicine...

Erratum

In the June 10, 2019, issue of The ASCO Post, a photo on page 69, in an article about the National Comprehensive Cancer Network Board of Directors, was incorrectly identified as Ronald Walters, MD, of The University of Texas MD Anderson Cancer Center. The photo was actually of Roland B. Walter,...

Joann Sweasy, PhD, Joins University of Arizona Cancer Center as Associate Director for Basic Sciences

Joann Sweasy, PhD, an expert in DNA repair and genomic instability, has joined the University of Arizona Cancer Center as Associate Director for Basic Sciences. Dr. Sweasy also has been appointed to a joint faculty position at the University of Arizona College of Medicine, Tucson, in the...

leukemia

FDA Approves First-Line Ivosidenib for IDH1-Mutated AML

On May 2, the U.S. Food and Drug Administration (FDA) expanded its approval of ivosidenib (Tibsovo) to include newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that ...

breast cancer
issues in oncology

Does Radioactive Iodine Treatment for Hyperthyroidism Increase the Risk of Cancer Mortality?

Findings from a study of patients who received radioactive iodine treatment for hyperthyroidism show a modest association between the dose of treatment and long-term risk of death from solid cancers, including breast cancer. The study, led by researchers at the National Cancer Institute (NCI), was...

lung cancer

Risk-Prediction Model Aims to Predict Incident Lung Cancer in Patients With a Pulmonary Nodule

A risk-prediction model developed using clinical and radiologic features could stratify individuals presenting with a lung nodule as having a high or low risk for lung cancer, according to a study published by Nemesure et al in Cancer Prevention Research. “While lung nodules are not...

kidney cancer
issues in oncology
immunotherapy

Benefit Seen With Targeted Therapies in Elderly and Medically Complex Patients With Metastatic RCC

Many elderly and medically complex patients with metastatic renal cell carcinoma (RCC)—who are often underrepresented in clinical trials—saw overall survival benefits from treatment with targeted therapies, according to a study that analyzed 13 years of data on Medicare patients...

breast cancer
survivorship

Mortality After Breast Cancer Among Childhood Cancer Survivors

In an analysis from the Childhood Cancer Survivor Study (CCSS) reported in the Journal of Clinical Oncology, Moskowitz et al found a significant increase in overall mortality among childhood cancer survivors who developed breast cancer vs matched controls. A numeric increase in breast cancer...

lymphoma
skin cancer

Anti-KIR3DL2 Monoclonal Antibody for Relapsed or Refractory Cutaneous T-Cell Lymphoma

In a phase I trial reported in The Lancet Oncology, Bagot et al found that IPH4102—a first-in-class monoclonal antibody targeting KIR3DL2—was safe and showed activity in patients with relapsed or refractory cutaneous T-cell lymphoma, particularly those with Sézary syndrome....

head and neck cancer

Long-Term Results of the Omission of Postoperative Radiation to the Pathologically Node-Negative Neck in Primary HNSCC

Long-term results of a single-institution phase II study reported in the Journal of Clinical Oncology by Contreras et al showed that the omission of postoperative radiation therapy to the pathologically negative (PN0) neck was associated with good outcomes among patients with primary head and neck...

Advertisement

Advertisement



;
Advertisement